Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Free Report

White Paper_2017_State of China Life Science

State of China Life Science - 2017H1

Over $10B invested in last 18 months! 

China Clinical Trials 2017

Analysis of IND and NDA applications and approvals in China 2011-2017

Download free report on life science investment in China

Week in Review: Amgen to Build China Presence with Partnerships/M&A

publication date: Feb 16, 2013
author/source: Richard Daverman, PhD

Deals and Financings

Amgen (NSDQ: AMGN) is planning to increase its participation in the China market,  using a combination of partnerships and M&A to build a presence (see story). It expects to have its own patented drugs on the China market by 2015. At the same time, the company has announced it will establish a biosimilar capability that will produce versions of its competitors’ biologic drugs. To make these drugs, Amgen is currently building a plant in Singapore, which will be completed by 2017. The company expects to generate $1 billion of revenues from biosimilars in emerging market countries.

China Shenghuo Pharmaceutical Holdings (Pinksheets: CKUN) has received a non-binding proposal to take the company private at a price of $.15 per share (see story). The stock is currently listed at $.14, a post-announcement rise of one-half cent. The offer comes from Lan's Int'l Medicine Investment Co., a company owned by the current management of Shenghuo that also owns 77.3% of Shenghuo’s outstanding common stock. The transaction will not be major, because Shenghuo currently has a market capitalization of less than $3 million.

Zhejiang Shanshi Medical Device has acquired the rights to distribute continuous, non-invasive hemodynamic patient monitoring systems manufactured by Tensys Medical, a San Diego medical device maker (see story). Over the five-year life of the contract, Shanshi expects to generate orders of up to $40 million of Tensys’ latest product, the TL-300, in China, Taiwan and Hong Kong.

Trials and Approvals

OxOnc Development LLP, an oncology company headquartered in Princeton, NJ, and Pfizer (NYSE: PFE) have signed a co-development agreement to conduct a Phase III clinical trial of a Pfizer cancer drug in China, Taiwan, Japan and South Korea (see story). The drug, crizotinib (marketed as Xalkori®), will be tested in patients with advanced non-small cell lung cancer who have a ROS1 (c-ros) gene rearrangement (ROS1-positive). The drug is already approved in the US, Europe, China and Japan for NSCLC patients with the ALK genetic variation.             

Celgene Corporation (NSDQ: CELG) was granted approval for Revlimid ® (lenalidomide) by the SFDA to treat multiple myeloma (see story). The approval, which is the first for Celgene in China, includes an Import Drug License. Revlimid is indicated for use in combination with dexamethasone in patients with relapsed or refractory multiple myeloma who have received at least one prior therapy. In 2006, the drug was approved for a similar indication in the US.

Disclosure: none.


Share this with colleagues:


ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Events
The 9th China Healthcare Investment Conference
Shanghai, China
March 27-29, 2018
Use chinabio18 for 20% discount